Drug intelligence / Profile preview

PP002

Development stage: Preclinical
Lead developer: Plano
Modality: Small Molecules
Administration: Intravenous, Intramuscular

Overview

PP002 is a generic sterile injectable analgesic currently in development by Plano Pharmaceuticals. It is part of a product development pipeline focused on addressing drug shortages in the North American market by providing essential generic sterile injectables. While the specific active pharmaceutical ingredient (API) has not been publicly disclosed, the drug is formulated for parenteral administration to provide pain relief. The development status for this product is currently listed as ongoing.

Targets

JIP1 (C-Jun-amino-terminal kinase-interacting protein 1)JNK (Mitogen-activated protein kinase kinase kinase family)

Beyond the preview

Go deeper on PP002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PP002.

Explore the full profile